within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG08_Ocrelizumab;
model Ocrelizumab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AG08;

  annotation(Documentation(
    info ="<html><body><p>Ocrelizumab is a humanized monoclonal antibody targeting CD20-positive B-cells, used for the treatment of relapsing and primary progressive forms of multiple sclerosis (MS). It is approved by regulatory agencies including the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic data in adult MS patients, both sexes, typically aged 18-55 years, with normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Newsome, SD, et al., &amp; Bermel, RA (2024). Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. <i>Annals of clinical and translational neurology</i> 11(12) 3215–3226. DOI:<a href=&quot;https://doi.org/10.1002/acn3.52229&quot;>10.1002/acn3.52229</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39460719/&quot;>https://pubmed.ncbi.nlm.nih.gov/39460719</a></p></li><li><p>Stahnke, AM, &amp; Holt, KM (2018). Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis. <i>The Annals of pharmacotherapy</i> 52(5) 473–483. DOI:<a href=&quot;https://doi.org/10.1177/1060028017747635&quot;>10.1177/1060028017747635</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29232960/&quot;>https://pubmed.ncbi.nlm.nih.gov/29232960</a></p></li><li><p>Reichert, JM (2015). Antibodies to watch in 2015. <i>mAbs</i> 7(1) 1–8. DOI:<a href=&quot;https://doi.org/10.4161/19420862.2015.988944&quot;>10.4161/19420862.2015.988944</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25484055/&quot;>https://pubmed.ncbi.nlm.nih.gov/25484055</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Ocrelizumab;
